查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1834022

头孢菌素类药物市场按药物类别、给药途径、剂型、最终用户、通路和应用划分——2025 年至 2032 年全球预测

Cephalosporin Drugs Market by Drug Class, Route Of Administration, Dosage Form, End User, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年头孢菌素药物市场将成长 206 亿美元，复合年增长率为 6.85%。

主要市场统计数据
基准年2024年 121.1亿美元
预计2025年 129.5亿美元
预测年份：2032年 206亿美元
复合年增长率（%） 6.85%

在不断变化的临床标准、供应压力和相关人员，头孢菌素治疗的策略框架

几十年来，头孢菌素类药物一直是抗菌治疗的基石，并不断适应不断变化的病原体易感性、临床实践和供应链现实。本导言将此类治疗药物置于当代新的监管预期、不断演变的抗药性模式以及不断变化的给药和配药偏好的背景下进行阐述。透过组装头孢菌素类药物置于这些相互交织的因素中，读者将理解为何涵盖药物类别、给药途径、剂型、最终用户环境、分销管道和临床用途的详细资讯对于策略决策至关重要。

临床相关人员越来越重视药物管理，同时兼顾快速有效的治疗需求。同时，製造商和经销商面临生产复杂性、原材料限制和价格压力等挑战。政策制定者和付款人正在实施有针对性的干预措施，这些措施会影响处方集的布局、筹资策略和报销结构。在此背景下，头孢菌素类药物并非一成不变，而是受到处方者行为、新出现的抗药性以及决定药物取得和使用的后勤因素的正面影响。

本引言阐明了研究范围和所采用的分析视角，为后续分析奠定了基础。它强调了整合临床、商业和管理观点以得出可操作结论的重要性。读者可以综合临床证据、供应方动态和相关人员奖励，为产品开发、产品组合管理和分销策略的决策提供参考。

透过诊断、严格的监管和不断发展的流通结构再形成头孢菌素疗法的关键变革力量

由于科学创新、抗生素管理监管格局以及整个医药供应链的结构性变化，头孢菌素的格局正在发生重大变化。新的诊断工具和快速药敏试验正在影响医疗保健中的处方，使得头孢菌素的使用更加精准，并在窄谱药物足够的情况下减少对经验性广谱频谱的暴露。同时，有关抗生素管理指标和生产品管的法律规范正在加强，推动产业在合规性、可追溯性和批次保证方面的投资增加。

在商业方面，分销模式正在发生变化，数位管道和专业物流加速了产品向门诊手术中心、居家照护机构和分散诊所的配送。对注射剂和粉剂低温运输及包装的投资，与对支持门诊护理的口服製剂的关注并存。这种转变也与临床实务息息相关：医院会根据疗效和供应弹性调整製剂，处方医师在选择药物时会考虑当地的抗药性模式。

综上所述，这些变化正在重塑竞争动态，迫使现有企业重新思考其产品组合，并迫使新参与企业寻求利基配方和给药系统。对于决策者而言，其影响显而易见：在製造、监管和商业营运方面的适应性将决定谁能引领下一波临床和物流需求。

不断变化的美国关税和贸易政策将如何对头孢菌素供应链的弹性和筹资策略施加累积压力

近期的关税改革和贸易政策调整对药品采购和分销产生了显着的连锁反应，尤其对头孢菌素类抗生素等供应链复杂的产品。影响原料药和成品的关税表变化可能会改变相对的采购经济性，迫使製造商重新评估其供应商布局，考虑将某些生产流程本地化，或调整其进出口策略，以减轻成本和前置作业时间的影响。

为此，製造外包和品牌所有者寻求替代筹资策略，包括多方采购、区域化供应流以及增加关键投入的库存缓衝。物流合作伙伴被要求提高到岸成本和时间的透明度，以便采购团队能够基于场景制定决策，平衡成本、韧性和合规性。医疗保健提供者和集团采购组织都在重新评估供应商合约和交付条款，以保持住院和门诊病人护理的连续性。

从临床角度来看，关税的间接影响将体现为製剂谈判和采购时间表的变化，这可能会改变某些剂型和给药途径的供应模式。其累积效应是更注重供应链风险管理和采购敏捷性，相关人员将优先考虑那些能够提供安全、合规且成本可预测的供应的合作伙伴。展望未来，将贸易政策意识融入产品生命週期规划和筹资策略的组织将更有能力维持市场进入并有效管理单价波动。

整合多维细分，将药物类别、给药途径、剂型、最终用户行为、分销管道和临床使用联繫起来

细緻的细分框架对于理解头孢菌素类药物的临床需求、生产复杂性和分销经济性如何交汇至关重要。在药物类别中，我们分析了第五代、第一代、第四代、第二代和第三代药物，并详细研究了第三代药物：头孢地尼、头孢克肟、头孢噻肟、头孢他啶和头孢曲松。这种按药物类别细分的药物揭示了不同的临床作用，一些药物在社区获得性感染中保持主要效用，而另一些药物则在医院获得性感染和严重性行为感染中发挥重要作用。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对医院环境中多重抗药性革兰氏阴性病菌感染的新兴第五代头孢菌素候选药物
  • 製药公司与生技Start-Ups之间的策略合作加速了新型头孢菌素抗生素的发现
  • 较低的製造成本和监管支持推动亚太地区非专利头孢菌素的生产
  • 整合抗生素管理计划，优化头孢菌素的使用并抑制抗生素抗药性趋势
  • 头孢菌素和β-内酰胺酶抑制剂联合治疗，用于克服频谱抗药性菌株
  • 政府定价和报销改革正在影响全球先进头孢菌素治疗的可近性和可负担性。

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 头孢菌素类药物市场（依药物类别）

  • 第五代
  • 第一代
  • 第四代
  • 第二代
  • 第三代
    • 头孢地尼
    • 头孢克肟
    • 头孢噻肟
    • 头孢他啶
    • 头孢曲松

9. 头孢菌素类药物市场依给药途径

  • 静脉
  • 口服

第 10 章头孢菌素类药物市场（按剂型）

  • 胶囊
  • 注射
  • 粉末
  • 药片

第 11 章头孢菌素类药物市场（依最终使用者）

  • 门诊手术中心
  • 诊所
  • 居家护理
  • 医院

12. 头孢菌素类药物市场依分销管道划分

  • 离线
  • 在线的

第十三章头孢菌素类药物市场应用

  • 淋病
  • 呼吸道感染疾病
    • 支气管炎
    • 肺炎
  • 败血症
  • 皮肤感染疾病
  • 尿道感染

14. 头孢菌素类药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章头孢菌素类药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 头孢菌素类药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
    • Viatris Inc.
    • Dr. Reddy's Laboratories Ltd
    • Sun Pharmaceutical Industries Ltd
    • Lupin Limited
    • Cipla Limited
    • Sanofi SA
Product Code: MRR-433AB1DC28F3

The Cephalosporin Drugs Market is projected to grow by USD 20.60 billion at a CAGR of 6.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.11 billion
Estimated Year [2025] USD 12.95 billion
Forecast Year [2032] USD 20.60 billion
CAGR (%) 6.85%

A strategic framing that positions cephalosporin therapeutics amid evolving clinical standards, supply pressures, and stakeholder incentives

Cephalosporin agents have remained a foundational component of antibacterial therapy for decades, adapting continuously to shifts in pathogen susceptibility, clinical practice, and supply chain realities. This introduction frames the therapeutic class within a contemporary context: the interplay of new regulatory expectations, evolving resistance patterns, and changing preferences in administration and dispensing. By situating cephalosporins within these converging forces, readers can appreciate why granular intelligence across drug classes, routes of administration, dosage forms, end-user settings, distribution channels, and clinical applications is essential for strategic decision-making.

Clinical stakeholders increasingly emphasize stewardship while balancing the need for rapid, effective therapy. Concurrently, manufacturers and distributors are navigating manufacturing complexities, raw material constraints, and pricing pressures. Policymakers and payers are introducing targeted interventions that influence formulary placement, procurement strategies, and reimbursement structures. Against this backdrop, the cephalosporin class is not static; it is actively shaped by prescriber behavior, emerging resistance, and logistical considerations that determine access and utilization.

This introduction sets the stage for the subsequent analysis by clarifying the scope and the analytical lenses applied across the study. It highlights the importance of integrating clinical, commercial, and operational perspectives to derive actionable conclusions. Readers will find a synthesis of clinical evidence, supply-side dynamics, and stakeholder incentives that collectively inform decisions about product development, portfolio management, and distribution strategies.

Key transformative forces reshaping cephalosporin therapeutics through diagnostics, regulatory rigor, and evolving distribution architectures

The cephalosporin landscape is undergoing transformative shifts driven by scientific innovation, regulatory emphasis on antimicrobial stewardship, and structural changes across the pharmaceutical supply chain. Novel diagnostic tools and rapid susceptibility testing influence prescribing at the point of care, enabling more targeted use of cephalosporins and reducing empirical broad-spectrum exposure where narrower agents suffice. Simultaneously, regulatory frameworks are tightening around antimicrobial stewardship metrics and quality control in manufacturing, prompting greater industry investment in compliance, traceability, and batch-level assurance.

On the commercial side, distribution models are shifting as digital channels and specialty logistics accelerate product reach to ambulatory surgical centers, homecare providers, and decentralized clinics. Investment in cold-chain infrastructure and packaging for injections and powders coexists with an increased emphasis on oral formulations to support outpatient therapy. These shifts also intersect with clinical practice: hospitals recalibrate formularies to reflect both efficacy and supply resilience, while prescribers weigh local resistance patterns when selecting agents.

Collectively, these changes reconfigure competitive dynamics, forcing incumbents to rethink portfolios and encouraging newcomers to pursue niche formulations or delivery systems. For decision-makers, the implication is clear: adaptability across manufacturing, regulatory affairs, and commercial operations will determine who capitalizes on the next wave of clinical and logistical demand.

How evolving United States tariff and trade policies exert cumulative pressures on cephalosporin supply chain resilience and procurement strategies

Tariff changes and trade policy adjustments instituted in recent periods have created notable ripple effects across pharmaceutical sourcing and distribution, particularly for products with complex supply chains such as cephalosporin antibiotics. Shifts in tariff schedules affecting active pharmaceutical ingredients and finished dosage forms change relative sourcing economics, prompting manufacturers to reassess supplier footprints, consider localization of certain production steps, or reconfigure import/export strategies to mitigate cost and lead-time impacts.

In response, contract manufacturers and brand owners have explored alternative procurement strategies including multi-sourcing, regionalizing supply flows, and increasing inventory buffers for critical inputs. Logistics partners have been asked to provide greater transparency on landed costs and timing, enabling procurement teams to model scenario-based decisions that balance cost, resilience, and regulatory compliance. Healthcare providers and group purchasing organizations are likewise re-evaluating supplier contracts and delivery terms to maintain continuity of care for inpatient and outpatient settings.

From a clinical perspective, the indirect effect of tariffs manifests as changes in formulary negotiations and procurement timelines, which can alter availability patterns for specific dosage forms and administration routes. The cumulative impact has been a heightened focus on supply chain risk management and sourcing agility, with stakeholders prioritizing partners that demonstrate secure, compliant, and cost-predictable supply arrangements. Going forward, organizations that integrate trade-policy awareness into product lifecycle planning and procurement strategies will be better positioned to preserve access and manage unit-cost volatility.

A multidimensional segmentation synthesis that links drug class, administration route, dosage form, end-user behavior, distribution channels, and clinical applications

A nuanced segmentation framework is essential for understanding where clinical demand, manufacturing complexity, and distribution economics converge within the cephalosporin class. Based on Drug Class, the analysis considers Fifth Generation, First Generation, Fourth Generation, Second Generation, and Third Generation agents, with the Third Generation examined in depth across Cefdinir, Cefixime, Cefotaxime, Ceftazidime, and Ceftriaxone. This drug-class granularity reveals divergent clinical roles: some generations maintain primary utility in community-acquired infections, while others serve critical roles in hospital-based and severe systemic infections.

Based on Route Of Administration, intravenous and oral modalities present different manufacturing and distribution considerations, with intravenous forms often demanding sterile production environments and more complex logistics, whereas oral forms favor broader outpatient access and retail distribution. Based on Dosage Form, capsules, injections, powders, and tablets each impose distinct formulation, stability, and packaging requirements that affect production timelines and supply-chain risk profiles. Based on End User, ambulatory surgical centers, clinics, homecare providers, and hospitals show varying procurement practices, reimbursement environments, and clinical protocols that influence product selection and inventory strategies.

Based on Distribution Channel, offline and online channels are reshaping how products reach prescribers and patients, influencing lead times, dispensing behaviors, and visibility into adoption trends. Based on Application, clinical demand is parsed across gonorrhea, respiratory tract infections, sepsis, skin infections, and urinary tract infections, with respiratory tract infections further distinguished by bronchitis and pneumonia subtypes. This multi-dimensional segmentation enables targeted assessment of where investment in supply chain improvements, clinical education, or formulation innovation will yield the highest operational and clinical returns.

Regional dynamics and regulatory nuances that determine access pathways, procurement behaviors, and distribution complexity across global territories

Regional dynamics exert a profound influence on clinical practice patterns, supply resilience, regulatory priorities, and commercial strategies across the cephalosporin landscape. In the Americas, healthcare systems emphasize centralized procurement mechanisms in hospitals and integrated delivery networks, while outpatient and retail channels continue to support broad access to oral formulations. Regulatory agencies in the region are increasingly focused on antimicrobial stewardship policies, affecting guideline-driven prescribing and formulary decisions that reflect evolving susceptibility profiles.

Europe, Middle East & Africa present a heterogeneous environment where regulatory frameworks, procurement modalities, and clinical guidelines diverge significantly across jurisdictions. This variation creates both challenges and opportunities: suppliers that tailor regulatory dossiers, quality assurances, and commercial strategies to regional expectations can access specialized segments such as hospital tenders and government procurement. Distribution complexity varies markedly across this combined region, with logistics providers needing to navigate diverse cold-chain requirements, import regulations, and local manufacturing incentives.

Asia-Pacific continues to be a dynamic arena shaped by rapid expansion of outpatient care, increased investment in local manufacturing capacity, and distinct clinical patterns that influence product preference. Countries in the region show a growing appetite for oral cephalosporins in community settings, alongside expanding hospital demand for injectable forms as tertiary care capacity grows. Across all regions, cross-border collaboration, regulatory harmonization efforts, and investments in supply-chain transparency will play critical roles in enabling consistent access to essential cephalosporin therapies.

Competitive and operational profiles of key industry participants emphasizing manufacturing resilience, regulatory compliance, and distribution agility

Industry participants in the cephalosporin space display a range of strategic priorities that reflect their positions across the product lifecycle, from active ingredient suppliers to finished-dosage manufacturers and specialized distributors. Leading players invest in sterile manufacturing capabilities, quality assurance systems, and regulatory affairs teams to support intravenous and injectable portfolios, while others focus on high-volume oral formulations optimized for ambulatory care and retail distribution. Strategic partnerships and contract manufacturing relationships remain central to scaling supply quickly and maintaining product continuity.

Competitive differentiation arises from several capabilities: robust compliance with evolving regulatory standards, flexible multi-site production to mitigate regional disruptions, and integrated cold-chain logistics for temperature-sensitive products. Companies that combine clinical engagement programs with real-world evidence generation strengthen their formulary positioning and prescriber trust. Additionally, investments in digital distribution channels and e-pharmacy partnerships have enabled some firms to expand their reach into online dispensing while preserving pharmacovigilance and patient support services.

For organizations evaluating competitors or potential partners, core considerations include the depth of sterile and non-sterile manufacturing capacity, the robustness of quality management systems, the ability to navigate regional regulatory environments, and the agility of distribution networks to support hospitals, clinics, ambulatory surgical centers, and homecare providers. Those that align operational excellence with targeted clinical support and flexible commercial models are best positioned to capture sustained clinical adoption.

Actionable industry priorities that enhance supply resilience, clinical alignment, and omnichannel distribution to preserve access and support stewardship

Industry leaders should pursue a set of actionable priorities that strengthen supply resilience, align clinical value with product positioning, and optimize commercial pathways to support appropriate access. First, enhance supply-chain flexibility by diversifying sources for critical inputs, qualifying regional contract manufacturers, and instituting scenario-based inventory planning that anticipates trade-policy and logistics disruptions. This approach minimizes single-point dependencies and supports consistent availability across hospitals, clinics, ambulatory surgical centers, and homecare settings.

Second, invest in sterile-production capabilities and quality assurance to support intravenous and injectable formats, while simultaneously optimizing oral dosage formulations for outpatient adherence and dispensing. Integrate clinical engagement programs that communicate appropriate use for indications such as gonorrhea, respiratory tract infections including bronchitis and pneumonia, sepsis, skin infections, and urinary tract infections, thereby reinforcing stewardship objectives and improving prescriber confidence.

Third, adopt omnichannel distribution strategies that combine offline strength in institutional procurement with online platforms that enhance retail and home-delivery access. Leverage digital tools to improve demand visibility and to coordinate replenishment across distribution nodes. Finally, align commercial and regulatory teams to proactively address regional requirements across the Americas, Europe, Middle East & Africa, and Asia-Pacific, ensuring dossier readiness, pharmacovigilance compliance, and tailored market access strategies. These actions will collectively improve organizational readiness to respond to clinical, regulatory, and logistical shifts.

A rigorous mixed-methods approach combining stakeholder interviews, regulatory review, and scenario-based analysis to ensure actionable and reproducible insights

The research approach integrates primary and secondary intelligence streams to construct a comprehensive view of clinical, operational, and commercial drivers affecting cephalosporin therapies. Primary inputs include structured conversations with clinicians across acute and ambulatory settings, procurement professionals in hospitals and group purchasing organizations, regulatory affairs specialists, and logistics providers responsible for cold-chain and sterile-product distribution. These engagements provided direct insight into prescribing behavior, procurement constraints, and operational pain points.

Secondary analysis encompassed a rigorous review of regulatory guidance, clinical literature on antimicrobial stewardship and cephalosporin utilization, publicly available pharmacovigilance data, and trade policy notices affecting pharmaceutical imports and exports. Synthesis relied on cross-validation between qualitative insights from stakeholder interviews and quantitative indicators such as manufacturing capacity distributions, distribution channel adoption metrics, and application-level clinical prevalence patterns. Analytical frameworks emphasized scenario planning to assess supply chain sensitivities and regulatory contingencies.

Throughout the methodology, emphasis was placed on transparency, reproducibility, and relevance to decision-makers. Assumptions and sources were documented and stress-tested through sensitivity checks, while regional differences were explicitly modeled to ensure that conclusions remain applicable across diverse healthcare systems. This methodological rigor underpins the report's recommendations and ensures they are operationally actionable for commercial, clinical, and regulatory teams.

Conclusive synthesis highlighting the operational, regulatory, and clinical imperatives necessary to secure sustainable access to cephalosporin therapies

The cephalosporin therapeutic area sits at the intersection of clinical necessity and complex supply dynamics, demanding coordinated responses from manufacturers, distributors, clinical leaders, and policymakers. The analysis underscores that success in this space requires more than product availability; it requires resilient manufacturing, regulatory agility, clear clinical communication, and distribution networks that can adapt to both institutional procurement and expanding outpatient care models.

Investment in sterile production for injectable formulations, paired with optimization of oral dosage forms for outpatient access, supports a balanced portfolio responsive to both hospital and community needs. Strengthening supplier diversity and logistics transparency reduces vulnerability to trade-policy shifts and raw material constraints. Simultaneously, integrating stewardship-focused clinical engagement preserves therapeutic efficacy and supports appropriate utilization across indications including gonorrhea, respiratory tract infections, sepsis, skin infections, and urinary tract infections.

In conclusion, organizations that proactively align operational capabilities, regulatory readiness, and clinical outreach will be best positioned to maintain access while navigating the evolving landscape. The path forward hinges on strategic investment, disciplined execution, and collaborative approaches that bridge clinical imperatives with supply-chain realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging fifth-generation cephalosporin candidates targeting multidrug resistant Gram-negative infections in hospital settings
  • 5.2. Strategic collaborations between pharmaceutical companies and biotech startups to accelerate novel cephalosporin antibiotic discovery
  • 5.3. Expansion of generic cephalosporin production in Asia Pacific driven by lower manufacturing costs and regulatory support
  • 5.4. Integration of antibiotic stewardship programs to optimize cephalosporin utilization and curb antimicrobial resistance trends
  • 5.5. Pipeline of combination therapies pairing cephalosporins with beta-lactamase inhibitors to overcome extended-spectrum resistant strains
  • 5.6. Government pricing and reimbursement reforms affecting access and affordability of advanced cephalosporin treatments globally

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cephalosporin Drugs Market, by Drug Class

  • 8.1. Fifth Generation
  • 8.2. First Generation
  • 8.3. Fourth Generation
  • 8.4. Second Generation
  • 8.5. Third Generation
    • 8.5.1. Cefdinir
    • 8.5.2. Cefixime
    • 8.5.3. Cefotaxime
    • 8.5.4. Ceftazidime
    • 8.5.5. Ceftriaxone

9. Cephalosporin Drugs Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Cephalosporin Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Powder
  • 10.4. Tablet

11. Cephalosporin Drugs Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Homecare
  • 11.4. Hospitals

12. Cephalosporin Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Cephalosporin Drugs Market, by Application

  • 13.1. Gonorrhea
  • 13.2. Respiratory Tract Infections
    • 13.2.1. Bronchitis
    • 13.2.2. Pneumonia
  • 13.3. Sepsis
  • 13.4. Skin Infections
  • 13.5. Urinary Tract Infections

14. Cephalosporin Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cephalosporin Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cephalosporin Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. F. Hoffmann-La Roche Ltd
    • 17.3.3. Teva Pharmaceutical Industries Ltd
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Viatris Inc.
    • 17.3.6. Dr. Reddy's Laboratories Ltd
    • 17.3.7. Sun Pharmaceutical Industries Ltd
    • 17.3.8. Lupin Limited
    • 17.3.9. Cipla Limited
    • 17.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-